Monday, February 08, 2021 5:50:15 AM
"The statistical analysis of the data remains ongoing. Relief expects top-line data from this trial to be reported once the required statistical analyses have been completed," it said, while affirming that collaboration partner NeuroRx Inc has initiated a phase 2/3 clinical trial investigating the role of inhaled RLF-100TM for treating of patients with severe COVID-19.
https://whbl.com/2021/02/08/relief-therapeutics-says-data-from-covid-drug-trial-to-emerge-this-month/
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM